Epilepsy Research UK Joins Tuberous Sclerosis Association in Funding Collaboration
Nappiness / Pixabay

Epilepsy Research UK Joins Tuberous Sclerosis Association in Funding Collaboration

  According to a recent announcement, Epilepsy Research UK has announced a funding collaboration with the Tuberous Sclerosis Association which will support the investigation of tuberous sclerosis complex (TSC)-associated epilepsy.…

Continue Reading Epilepsy Research UK Joins Tuberous Sclerosis Association in Funding Collaboration

Researchers Created Mini-Kidneys to Identify Tuberous Sclerosis Complex and Solve a Medical Mystery

Tuberous sclerosis complex (TSC) is classified as a rare genetic disorder that causes typically benign tumors in the brain, skin, heart, kidneys, or lungs. As described in a recent article…

Continue Reading Researchers Created Mini-Kidneys to Identify Tuberous Sclerosis Complex and Solve a Medical Mystery

Facial Angiofibroma Associated with Tuberous Sclerosis Complex Now Has an FDA Approved Topical Therapy

Nobelpharma has just announced the FDA approval of sirolimus .2% gel (called Hyftor). It is now the first approved, topical therapy for facial angiofibroma associated with the rare condition tuberous…

Continue Reading Facial Angiofibroma Associated with Tuberous Sclerosis Complex Now Has an FDA Approved Topical Therapy
Study Reveals Gene Therapy as a Possible Tuberous Sclerosis Complex Treatment
source: pixabay.com

Study Reveals Gene Therapy as a Possible Tuberous Sclerosis Complex Treatment

According to a story from news-medical.net, a team of scientists affiliated with Massachusetts General Hospital has conducted a study revealing that gene therapy could be an effective treatment for tuberous…

Continue Reading Study Reveals Gene Therapy as a Possible Tuberous Sclerosis Complex Treatment
Tuberous Sclerosis Complex: CBD Oral Solution Epidiolex Approved to Treat Seizures
source: pixabay.com

Tuberous Sclerosis Complex: CBD Oral Solution Epidiolex Approved to Treat Seizures

According to a story from GlobeNewswire, the biopharmaceutical company GW Pharmaceuticals plc recently announced that its CBD oral solution Epidiolex® has recently been approved as a treatment for seizures associated…

Continue Reading Tuberous Sclerosis Complex: CBD Oral Solution Epidiolex Approved to Treat Seizures
Congenital Ichthyosis and Tuberous Sclerosis Complex Clinical Trials are Now Enrolling Patients
source: pixabay.com

Congenital Ichthyosis and Tuberous Sclerosis Complex Clinical Trials are Now Enrolling Patients

Timber Pharmaceuticals focuses on rare diseases of dermatologic origin. These include scleroderma, congenital ichthyosis, tuberous sclerosis complex, and facial angiofibromas. They are currently working on two clinical trials. Trial 1…

Continue Reading Congenital Ichthyosis and Tuberous Sclerosis Complex Clinical Trials are Now Enrolling Patients

Rare Epilepsy Updates:  One New Drug, Two Clinical Trials, and Orphan Drug Designation

  A recent article published in Globe Newswire heralded Marinus Pharmaceuticals’ new drug, ganaxolone. The drug has been studied in over 1600 patients and is now being tested in two clinical…

Continue Reading Rare Epilepsy Updates:  One New Drug, Two Clinical Trials, and Orphan Drug Designation
Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
cbd123 / Pixabay

Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD

According to a press release from the British biotechnology company GW Pharmaceuticals, the company has reported successful results at the conclusion of its phase 3 trial of tuberous sclerosis complex…

Continue Reading Positive Results at End of Phase 3 Trial of Candidate Tuberous Sclerosis Complex Drug – CBD
Patient Activists are Speaking Out After NHS England Decided Not to Fund a Drug to Treat TSC-Associated Epilepsy
https://pixabay.com/en/child-girl-face-expression-view-632602/

Patient Activists are Speaking Out After NHS England Decided Not to Fund a Drug to Treat TSC-Associated Epilepsy

The National Health Service (NHS) England is facing criticism following their decision not to fund the drug everolimus as a treatment for tuberous sclerosis complex associated refractory epilepsy. In comparison,…

Continue Reading Patient Activists are Speaking Out After NHS England Decided Not to Fund a Drug to Treat TSC-Associated Epilepsy